A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults

BACKGROUND: Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B p24, RT, Nef, p17 fusion protein (F4/AS01) plus a non-replicating adenovirus 35 expressing clade A Gag, RT, Int and Nef (Ad35-GRIN) may lead to a unique immune profile, inducing both stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Omosa-Manyonyi, Gloria, Mpendo, Juliet, Ruzagira, Eugene, Kilembe, William, Chomba, Elwyn, Roman, François, Bourguignon, Patricia, Koutsoukos, Marguerite, Collard, Alix, Voss, Gerald, Laufer, Dagna, Stevens, Gwynn, Hayes, Peter, Clark, Lorna, Cormier, Emmanuel, Dally, Len, Barin, Burc, Ackland, Jim, Syvertsen, Kristen, Zachariah, Devika, Anas, Kamaal, Sayeed, Eddy, Lombardo, Angela, Gilmour, Jill, Cox, Josephine, Fast, Patricia, Priddy, Frances
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427332/
https://www.ncbi.nlm.nih.gov/pubmed/25961283
http://dx.doi.org/10.1371/journal.pone.0125954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427332/
https://www.ncbi.nlm.nih.gov/pubmed/25961283
http://dx.doi.org/10.1371/journal.pone.0125954

Ejemplares similares